Recent Updates
Recently added Catalysts

BRAF V600 Mutated Melanoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$5.7Buniverse median $1.20B
Allocated capital$1.9B$5.7B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank101/299crowding rank 125

BRAF V600 Mutated Melanoma is uncontested. Erasca (ERAS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Naporafenib in phase 3.

There is no public comparable to price it against. ERAS spreads its $5.7B market cap across 3 indications, so $1.9B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$1.9B of allocated capital sits in BRAF V600 Mutated Melanoma, ranking it 101st of 299 indications by the money committed to it.

Companies developing drugs for BRAF V600 Mutated Melanoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ERASErascaNaporafenibPhase 32$5.7BNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why BRAF V600 Mutated Melanoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. BRAF V600 Mutated Melanoma has one competitor and a median of $5.7B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Metastatic Solid Tumors1 company · $1.9B · median $5.7BUncontestedIDH-Mutant Astrocytoma, Grade 23 companies · $2.0B · median $2.5BConcentrated betNon-Hodgkin's Lymphoma7 companies · $1.7B · median $239MKnife fightDesmoid Tumor1 company · $1.5B · median $3.1BUncontestedIntrahepatic Cholangiocarcinoma1 company · $1.5B · median $6.1BUncontestedGastrointestinal Cancer1 company · $1.5B · median $6.1BUncontestedSystemic Mastocytosis1 company · $1.5B · median $6.1BUncontestedGastrointestinal Stromal Tumor3 companies · $2.3B · median $1.6BConcentrated bet

BRAF V600 Mutated Melanoma pipeline questions

Which biotech companies are developing drugs for BRAF V600 Mutated Melanoma?

Erasca (ERAS, Naporafenib, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in BRAF V600 Mutated Melanoma.

How advanced is the BRAF V600 Mutated Melanoma pipeline?

Of the 1 clinical-stage programme in BRAF V600 Mutated Melanoma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for BRAF V600 Mutated Melanoma?

No. ERAS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in BRAF V600 Mutated Melanoma, which is why the indication is classified as uncontested.

When is the next BRAF V600 Mutated Melanoma catalyst?

The next dated catalyst in BRAF V600 Mutated Melanoma is ERAS on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map